Barinthus Biotherapeutics plc (BRNS) — Strategic Asset Allocation Index

Latest as of September 2022: 5.9%

Barinthus Biotherapeutics plc (BRNS) has a Strategic Asset Allocation Index of 5.9% as of September 2022. Strategic assets (PP&E of $14.32 Million plus long-term investments of $-) total $14.32 Million, measured against net assets of $244.15 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Barinthus Biotherapeutics plc (BRNS) balance sheet quality index to measure how much of total assets are equity-financed.

SAAI

5.9%
Strategic Assets / Net Assets

Strategic Assets

$14.32 Million
PP&E + LT Investments

PP&E

$14.32 Million
USD

Net Assets

$244.15 Million
USD

Barinthus Biotherapeutics plc Strategic Asset Allocation Index (2021–2021)

This chart shows how Barinthus Biotherapeutics plc's Strategic Asset Allocation Index has evolved across 1 annual periods from 2021 to 2021. As of September 2022, the index stands at 5.9%, representing strategic assets of $14.32 Million against net assets of $244.15 Million USD. For live market cap and overall valuation, see market value of Barinthus Biotherapeutics plc.

Annual Strategic Asset Allocation Index for Barinthus Biotherapeutics plc (2021–2021)

The table below presents the year-by-year Strategic Asset Allocation Index for Barinthus Biotherapeutics plc from 2021 to 2021, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Barinthus Biotherapeutics plc book value and equity for net asset value and shareholders' equity analysis.

Year SAAI Strategic Assets (USD) PP&E LT Investments Net Assets Change (pp)
2021 0.7% $1.83 Million $1.83 Million $- $252.56 Million
pp = percentage points